facebook
twitter
rss
account
search
search
 

Military testing malaria vaccine

Oct. 8, 2012 at 12:25 PM   |   Comments

GAITHERSBURG, Md., Oct. 8 (UPI) -- Bio-pharmaceutical company GenVec Inc. is to provide clinical supplies of its malaria vaccine to the U.S. Naval Medical Research Center for more evaluation.

The vaccine is a proprietary adenovector delivery system capable of generating strong immune responses while avoiding vector-specific immunity.

Clinical data from a Phase 1 malaria vaccine trial conducted by NMRC and the Walter Reed Army Institute of Research, using GenVec adenovector technology coupled with DNA plasmid priming, indicated the vaccine "was safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions," GenVec said.

"We appreciate the U.S. military's continued commitment to the worldwide problem of malaria and its support of malaria vaccine development," said Joseph Bruder, director of research and head of GenVec's malaria program. "Work under this agreement will build upon the encouraging clinical results previously demonstrated."

The contract for supply of the vaccine for further clinical testing is worth about $3.5 million.

© 2012 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Most Popular
1
Iran wants to develop mini-LNG plants
2
Slovakia plants seed in Ukrainian gas sector
3
Twitter to remove pictures of deceased on family's request
4
Iraq worried by terrorist ties to oil
5
EPA takes charge in Ohio River diesel spill
Trending News
Video
x
Feedback